[go: up one dir, main page]

MX2011007712A - Los ácido sórbico y benzoico y sus derivados aumentan la actividad de un neurofarmacéutico. - Google Patents

Los ácido sórbico y benzoico y sus derivados aumentan la actividad de un neurofarmacéutico.

Info

Publication number
MX2011007712A
MX2011007712A MX2011007712A MX2011007712A MX2011007712A MX 2011007712 A MX2011007712 A MX 2011007712A MX 2011007712 A MX2011007712 A MX 2011007712A MX 2011007712 A MX2011007712 A MX 2011007712A MX 2011007712 A MX2011007712 A MX 2011007712A
Authority
MX
Mexico
Prior art keywords
benzoic acid
disorder
sorbic
neuropharmaceutical
sorbic acid
Prior art date
Application number
MX2011007712A
Other languages
English (en)
Other versions
MX353752B (es
Inventor
Guochuan Emil Tsai
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of MX2011007712A publication Critical patent/MX2011007712A/es
Publication of MX353752B publication Critical patent/MX353752B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos y composiciones para tratar trastornos neuropsiquiátricos como esquizofrenia, depresión, trastorno por déficit de atención, deficiencia cognitiva leve, demencia y trastorno bipolar. Los métodos consisten en administrar a un paciente al que se le haya diagnosticado un trastorno neuropsiquiátrico (por ejemplo, esquizofrenia, depresión, trastorno por déficit de atención, deficiencia cognitiva leve, demencia, trastorno bipolar, etc.) o esté en riesgo de padecer u trastorno neuropsiquiátrico, ácido benzoico, una sal del ácido benzoico o un derivado del ácido benzoico y/o ácido sórbico, una sal del ácido sórbico o un derivado del ácido sórbico, combinado con un neurofármaco (por ejemplo, un antipsicótico, un antidepresivo, medicamentos para el trastorno por déficit de atención e hiperactividad, deficiencia cognitiva o demencia, etc.), en donde el ácido benzoico, la sal del ácido benzoico o el derivado del ácido benzoico y/o el ácido sórbico, la sal del ácido sórbico o el derivado del ácido sórbico, está en una cantidad suficiente para aumentar la eficacia del neurofármaco.
MX2011007712A 2009-01-20 2010-01-19 Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco. MX353752B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14593109P 2009-01-20 2009-01-20
PCT/US2010/021420 WO2010085452A1 (en) 2009-01-20 2010-01-19 Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

Publications (2)

Publication Number Publication Date
MX2011007712A true MX2011007712A (es) 2011-12-14
MX353752B MX353752B (es) 2018-01-26

Family

ID=42354348

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017002151A MX374638B (es) 2009-01-20 2010-01-19 Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.
MX2011007712A MX353752B (es) 2009-01-20 2010-01-19 Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
MX2017002152A MX380715B (es) 2009-01-20 2010-01-19 Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017002151A MX374638B (es) 2009-01-20 2010-01-19 Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017002152A MX380715B (es) 2009-01-20 2010-01-19 Los acidos sorbico y benzoico y sus derivados aumentan la actividad de un neurofarmaco.

Country Status (12)

Country Link
US (5) US9649304B2 (es)
EP (3) EP3006023B1 (es)
JP (1) JP5675650B2 (es)
CN (1) CN102292094B (es)
AU (1) AU2010206886B2 (es)
BR (1) BRPI1007173A2 (es)
CA (2) CA3037010A1 (es)
DK (2) DK3006024T3 (es)
ES (2) ES2731228T3 (es)
HR (2) HRP20170089T1 (es)
MX (3) MX374638B (es)
WO (1) WO2010085452A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085452A1 (en) 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
WO2011017319A1 (en) * 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
JP5751109B2 (ja) * 2011-09-20 2015-07-22 ニプロ株式会社 生体試料中の馬尿酸およびメチル馬尿酸のそれぞれの濃度を測定する方法
HK1211239A1 (en) * 2012-08-06 2016-05-20 S1 Biopharma, Inc. Treatment regimens
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2014168727A1 (en) * 2013-03-15 2014-10-16 Shire Llc Fixed dose combination treatment for schizophrenia
KR102162073B1 (ko) * 2014-03-24 2020-10-07 가오슝 창 궁 메모리얼 하스피털 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도
EP3335126A4 (en) 2015-08-11 2019-05-01 Cognoa, Inc. METHOD AND DEVICE FOR DETERMINING DEVELOPMENT PROGRESS WITH ARTIFICIAL INTELLIGENCE AND USER ENTRY
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
US10653639B2 (en) 2016-05-16 2020-05-19 Cv Sciences, Inc. Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
CA3027300C (en) 2016-06-13 2023-08-08 Syneurx International (Taiwan) Corp. Co-crystals of lithium benzoate and uses thereof
JP6958922B2 (ja) * 2016-06-13 2021-11-02 シニュークス インターナショナル（タイワン）コーポレイション 安息香酸ナトリウムの共結晶及びその使用
CN109562089A (zh) * 2016-06-13 2019-04-02 心悦生医股份有限公司 苯甲酸锂用于治疗中枢神经系统疾病的用途
KR102728012B1 (ko) * 2016-09-23 2024-11-11 델포어, 인코포레이티드 소분자 치료제 화합물 조성물
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
WO2018090009A1 (en) * 2016-11-14 2018-05-17 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
EP4400171A3 (en) * 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
RU2764443C2 (ru) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
WO2018148365A1 (en) 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
TWI626043B (zh) * 2017-06-13 2018-06-11 心悅生醫股份有限公司 苯甲酸鋰用於治療中樞神經系統疾病的用途
BR112019027037B1 (pt) 2017-06-26 2022-04-05 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico contendo asenapina e polímero híbrido acrílico de silicone, e processo para fabricar uma camada contendo asenapina para uso no referido sistema
JP6550426B2 (ja) * 2017-07-26 2019-07-24 カオシュン・チャン・グン・メモリアル・ホスピタル 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
TWI752282B (zh) * 2017-11-22 2022-01-11 林潔欣 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途
CN112118838A (zh) 2017-12-05 2020-12-22 赛诺维信制药公司 非外消旋混合物及其用途
CN118955352A (zh) 2017-12-05 2024-11-15 赛诺维信制药公司 晶体形式及其制备方法
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
KR102051624B1 (ko) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물
WO2020198065A1 (en) 2019-03-22 2020-10-01 Cognoa, Inc. Personalized digital therapy methods and devices
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN119949562A (zh) * 2020-03-27 2025-05-09 深圳市合瑞生物科技有限公司 组合物及其制品
US11376277B2 (en) * 2020-06-01 2022-07-05 Celagenex Research (India) Pvt. Ltd. Synergistic medicinal compositions for treating dysfunctional D-serine signaling
WO2023031103A1 (en) * 2021-08-30 2023-03-09 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
JP2025503457A (ja) * 2021-12-16 2025-02-04 ザ ユナイテッド ステイツ ガバメント アズ リプレゼンティド バイ ザ デパートメント オブ ヴェテランズ アフェアーズ 神経系損傷及び障害の治療のための安息香酸塩
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3498989A (en) 1969-04-16 1970-03-03 American Home Prod Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof
US3870715A (en) * 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4041174A (en) * 1974-08-16 1977-08-09 Rom-Amer Pharmaceuticals, Ltd. Method of treating depression
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
GB8819494D0 (en) * 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
DE4340273A1 (de) 1993-11-26 1995-06-01 Karla Dr Lehmann Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
WO2001041707A2 (en) * 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
EA005621B1 (ru) 2000-07-21 2005-04-28 Х.Лундбекк А/С Гетероциклические соединения в качестве ингибиторов транспортера глицина
PT1783118E (pt) 2000-08-14 2008-08-19 Teva Pharma Preparação de risperidona
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2002066672A2 (en) 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
AU2002339696A1 (en) 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
JP2007502332A (ja) * 2003-05-30 2007-02-08 マイクロバイア インコーポレイテッド 記憶および認知保護法
JP2006526635A (ja) * 2003-06-02 2006-11-24 サマリタン，ファーマスーティカルス，インク． 血清中コルチゾール量を調節する方法および組成物
CN102010382A (zh) 2003-12-29 2011-04-13 塞普拉科公司 苯并[d]异噁唑-3-醇DAAO抑制剂
DE602005027308D1 (de) 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
US20050267176A1 (en) * 2004-02-18 2005-12-01 Sepracor Inc. Dopamine-agonist combination therapy for improving sleep quality
JP4756031B2 (ja) 2004-03-24 2011-08-24 メルク・シャープ・エンド・ドーム・コーポレイション ヘテロアリールピペリジングリシン輸送体インヒビター
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
US20110045065A1 (en) 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
GB0603181D0 (en) * 2006-02-17 2006-03-29 Merck Sharp & Dohme Treatment of neurodegenerative and psychiatric diseases
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
US20080070984A1 (en) 2006-09-15 2008-03-20 Tran Pierre V Compositions and Methods of Treating Schizophrenia
WO2010085452A1 (en) 2009-01-20 2010-07-29 Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical

Also Published As

Publication number Publication date
EP3006023A1 (en) 2016-04-13
US10039730B2 (en) 2018-08-07
US20170181989A1 (en) 2017-06-29
BRPI1007173A2 (pt) 2016-02-23
US20100189818A1 (en) 2010-07-29
US20150099015A1 (en) 2015-04-09
ES2731228T3 (es) 2019-11-14
CA3037010A1 (en) 2010-07-29
CN102292094B (zh) 2013-08-14
CN102292094A (zh) 2011-12-21
JP2012515720A (ja) 2012-07-12
ES2615884T3 (es) 2017-06-08
WO2010085452A1 (en) 2010-07-29
US9675604B2 (en) 2017-06-13
CA2750028C (en) 2019-05-07
AU2010206886A1 (en) 2011-09-08
CA2750028A1 (en) 2010-07-29
EP2389187A1 (en) 2011-11-30
US20190151301A1 (en) 2019-05-23
EP2389187B1 (en) 2016-11-16
MX374638B (es) 2025-03-06
MX353752B (es) 2018-01-26
US11529342B2 (en) 2022-12-20
HRP20170089T1 (hr) 2017-03-24
US20170189358A1 (en) 2017-07-06
EP2389187A4 (en) 2013-12-04
AU2010206886B2 (en) 2016-05-05
WO2010085452A9 (en) 2011-01-06
DK2389187T3 (en) 2017-02-20
EP3006024B1 (en) 2019-03-20
US10149845B2 (en) 2018-12-11
DK3006024T3 (da) 2019-06-03
HRP20190933T1 (hr) 2019-07-26
US9649304B2 (en) 2017-05-16
EP3006024A1 (en) 2016-04-13
MX380715B (es) 2025-03-12
JP5675650B2 (ja) 2015-02-25
EP3006023B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
MX2011007712A (es) Los ácido sórbico y benzoico y sus derivados aumentan la actividad de un neurofarmacéutico.
UY31821A (es) Compuestos y composiciones como inhibidores de quinasa
BR112014030386A2 (pt) compostos e composições para modular a atividade de egfr
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
CO6430427A2 (es) Derivados de benzofuranilo
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
UY34654A (es) Inhibidores de la beta-secretasa
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
BR112015001759A8 (pt) agentes de modulação de atx, seus usos e composição farmacêutica
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
CR20110103A (es) Heteroarilos sustituidos
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
CL2014000210A1 (es) Una composicion de prodroga que comprende al menos un conjugado de metilfenidato; kit farmaceutico que la comprende, util para el tratamiento de una enfermedad o condicion que requiere estimulacion del sistema nervioso tal como un trastorno de hiperactividad con deficit de atencion y depresion.
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
CL2011000488A1 (es) Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus.
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
UA109260C2 (uk) Хромонові похідні, спосіб їх одержання та їх терапевтичні застосування
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
SV2010003694A (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de leucotrieno a4 hidrolasa
CO6331434A2 (es) Nuevos compuestos

Legal Events

Date Code Title Description
FG Grant or registration